Ignet

Gene Information

Gene symbol: ZNF77

Gene name: zinc finger protein 77

HGNC ID: 13150

Synonyms: pT1

Related Genes

#	Gene Symbol	Number of hits
1	IFNA2	1 hits
2	PTCRA	1 hits

Related Sentences

#	PMID	Sentence
1	1302409	Our 6-year experience with BCG Pasteur strain (and Connaught strain, respectively) in tumour stages pTis, pTa and pT1 (G I-II) shows lasting remission in 88.5% (73%) of 78 (26) patients after transurethral resection of the tumour.
2	1408061	Our 5-year experience with BCG in the tumor stage pTis, pTa and pT1, G I-II shows a lasting remission of 88.5% (73%) in 78 (26) patients treated with BCG preparation Pasteur (Connaught) after transurethral resection.
3	1796850	All patients had stage pTa or pT1 transitional cell carcinoma or carcinoma in situ without other concurrent malignancies.
4	1819200	After transurethral resection (T.U.R) and open surgery of 178 patients with superficial bladder tumors (pTa, pT1) we applied intravesical Romanian (modified Pasteur strain) Bacille Calmette-Guérin therapy.
5	1904120	From June 1985 to October 1988, 42 newly diagnosed patients with superficial bladder carcinoma (pTa or pT1) were treated by transurethral tumor resection and subsequent five daily instillations of mitomycin C.
6	1997698	All patients had stage pTa or pT1 transitional cell carcinoma or carcinoma in situ without other concurrent malignancies.
7	7853577	Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ.
8	8032830	Marker tumour response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
9	8727805	The Dutch Cooperative Trial evaluated mitomycin versus BCG-Tice versus BCG-RIVM in 469 patients with pTA/pT1 carcinoma and CIS of the urinary bladder after TUR.
10	9615929	[Results of BCG in the treatment of pTa and pT1 bladder tumors.
11	9752330	Superficial bladder tumor defined as pTa, pT1 and pTis stage is one of the most common cancer disease in the world.
12	10810268	To evaluate cytological changes of urothelial cells with intravesical instillation therapy of the bacillus Calmette-Guérin (BCG), cytological specimens of voided urine from patients with superficial bladder cancer (pTa and pT1) treated with intravesical BCG therapy were examined.
13	12017377	Between July 1994 and July 2001, all patients with superficial transitional cell carcinoma (TCC) of urinary bladder (pT1 and pTa), 7 days after undergoing transurethral resection of tumor were subjected to intravesical instillation of 60 mg BCG (Danish 1331) combined with 5 million IU interferon alpha-2b (Intron-A) mixed with 50 ml of physiological saline weekly for 8 weeks, then fortnightly for 8 weeks, then monthly for 8 weeks, followed by maintenance dose at the end of the 9th, 12th, 18th, 24th months.
14	12090337	To evaluate the relative importance of clinicopathological factors affecting recurrence, progression, and survival in patients with superficial bladder cancer (pTa and pT1) undergoing bacillus Calmette-Guerin (BCG) therapy (Tokyo 172 strain), we reviewed data for 146 patients treated between 1985 and 1998.
15	15628536	Nineteen patients with high-grade superficial bladder cancer (pTa, pT1) and 5 patients with grade 3 carcinoma in situ (CIS) received intravesical instillation of BCG after transurethral resection of the bladder tumor (BCG group and CIS-BCG group).
16	15628536	Our results suggest that BCG therapy prevents grade 3 superficial bladder cancer (pT1, pTa) recurrence.
17	15628536	Nineteen patients with high-grade superficial bladder cancer (pTa, pT1) and 5 patients with grade 3 carcinoma in situ (CIS) received intravesical instillation of BCG after transurethral resection of the bladder tumor (BCG group and CIS-BCG group).
18	15628536	Our results suggest that BCG therapy prevents grade 3 superficial bladder cancer (pT1, pTa) recurrence.
19	18609266	Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.